For research use only. Not for therapeutic Use.
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy[1].
Labetuzumab (0.5 mg/rat; i.v.; single) inhibits tumor growth in vivo[1].
| Catalog Number | I043218 |
| CAS Number | 219649-07-7 |
| Purity | ≥95% |
| Reference | [1]. Stein R, et al. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther. 2004 Dec;3(12):1559-64. |
